Literature DB >> 26195697

Improving the Evidence Base for Treating Older Adults With Cancer: American Society of Clinical Oncology Statement.

Arti Hurria1, Laura A Levit2, William Dale2, Supriya G Mohile2, Hyman B Muss2, Louis Fehrenbacher2, Allison Magnuson2, Stuart M Lichtman2, Suanna S Bruinooge2, Enrique Soto-Perez-de-Celis2, William P Tew2, Michael A Postow2, Harvey J Cohen2.   

Abstract

The American Society of Clinical Oncology (ASCO) convened a subcommittee to develop recommendations on improving the evidence base for treating older adults with cancer in response to a critical need identified by the Institute of Medicine. Older adults experience the majority of cancer diagnoses and deaths and make up the majority of cancer survivors. Older adults are also the fastest growing segment of the US population. However, the evidence base for treating this population is sparse, because older adults are underrepresented in clinical trials, and trials designed specifically for older adults are rare. The result is that clinicians have less evidence on how to treat older adults, who represent the majority of patients with cancer. Clinicians and patients are forced to extrapolate from trials conducted in younger, healthier populations when developing treatment plans. This has created a dearth of knowledge regarding the risk of toxicity in the average older patient and about key end points of importance to older adults. ASCO makes five recommendations to improve evidence generation in this population: (1) Use clinical trials to improve the evidence base for treating older adults with cancer, (2) leverage research designs and infrastructure for generating evidence on older adults with cancer, (3) increase US Food and Drug Administration authority to incentivize and require research involving older adults with cancer, (4) increase clinicians' recruitment of older adults with cancer to clinical trials, and (5) use journal policies to improve researchers' reporting on the age distribution and health risk profiles of research participants.
© 2015 by American Society of Clinical Oncology.

Entities:  

Mesh:

Year:  2015        PMID: 26195697     DOI: 10.1200/JCO.2015.63.0319

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  102 in total

1.  Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study.

Authors:  Vivian E von Gruenigen; Helen Q Huang; Jan H Beumer; Heather A Lankes; William Tew; Thomas Herzog; Arti Hurria; Robert S Mannel; Tina Rizack; Lisa M Landrum; Peter G Rose; Ritu Salani; William H Bradley; Thomas J Rutherford; Robert V Higgins; Angeles Alvarez Secord; Gini Fleming
Journal:  Gynecol Oncol       Date:  2017-01-13       Impact factor: 5.482

2.  Health care disparities among octogenarians and nonagenarians with stage III lung cancer.

Authors:  Richard J Cassidy; Xinyan Zhang; Jeffrey M Switchenko; Pretesh R Patel; Joseph W Shelton; Sibo Tian; Ronica H Nanda; Conor E Steuer; Rathi N Pillai; Taofeek K Owonikoko; Suresh S Ramalingam; Felix G Fernandez; Seth D Force; Theresa W Gillespie; Walter J Curran; Kristin A Higgins
Journal:  Cancer       Date:  2018-01-08       Impact factor: 6.860

Review 3.  Advanced pancreatic cancer clinical trials: The continued underrepresentation of older patients.

Authors:  Maya N White; Efrat Dotan; Paul J Catalano; Dana B Cardin; Jordan D Berlin
Journal:  J Geriatr Oncol       Date:  2018-12-18       Impact factor: 3.599

4.  Cancer in older adults: understanding cause and effects of chemotherapy-related toxicities.

Authors:  Vijaya R Bhatt
Journal:  Future Oncol       Date:  2019-07-24       Impact factor: 3.404

5.  Changes in the Use of Comprehensive Geriatric Assessment in Clinical Trials for Older Patients with Cancer over Time.

Authors:  Olivia Le Saux; Claire Falandry; Hui K Gan; Benoit You; Gilles Freyer; Julien Péron
Journal:  Oncologist       Date:  2019-02-01

6.  The State of Cancer Care in America, 2016: A Report by the American Society of Clinical Oncology.

Authors: 
Journal:  J Oncol Pract       Date:  2016-03-15       Impact factor: 3.840

Review 7.  Management of locally advanced rectal cancer in the elderly: a critical review and algorithm.

Authors:  Lara Hathout; Nell Maloney-Patel; Usha Malhotra; Shang-Jui Wang; Sita Chokhavatia; Ishita Dalal; Elizabeth Poplin; Salma K Jabbour
Journal:  J Gastrointest Oncol       Date:  2018-04

8.  Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer.

Authors:  Arti Hurria; Enrique Soto-Perez-de-Celis; Jacob B Allred; Harvey Jay Cohen; Anait Arsenyan; Karla Ballman; Jennifer Le-Rademacher; Aminah Jatoi; Julie Filo; Jeanne Mandelblatt; Jacqueline M Lafky; Gretchen Kimmick; Heidi D Klepin; Rachel A Freedman; Harold Burstein; Julie Gralow; Antonio C Wolff; Gustav Magrinat; Myra Barginear; Hyman Muss
Journal:  J Am Geriatr Soc       Date:  2018-08-26       Impact factor: 5.562

9.  Factors Associated With Unplanned Hospitalizations Among Patients With Nonmetastatic Colorectal Cancers Intended for Treatment in the Ambulatory Setting.

Authors:  Kristen L Fessele; Matthew J Hayat; Deborah K Mayer; Robert L Atkins
Journal:  Nurs Res       Date:  2016 Jan-Feb       Impact factor: 2.381

10.  Chemotherapy Toxicity Risk Score for Treatment Decisions in Older Adults with Advanced Solid Tumors.

Authors:  Tomohiro F Nishijima; Allison M Deal; Grant R Williams; Hanna K Sanoff; Kirsten A Nyrop; Hyman B Muss
Journal:  Oncologist       Date:  2018-01-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.